Microbial Efficacy Analysis of Potentox, a Fixed Dose Combination of Cefepime Amikacin with Cefepime and Amikacin Alone in a Citrobacter Braaki, Mycobacterium Smegmatis, Acinetobacter Baumanii and Neisseria mucosa
Sanjay Mohan Shrivastava,* Sanjeev Kumar Shukla, Shailesh Kumar and Manu ChaudharyVenus Medicine Research Centre, Hill Top Industrial Estate, Jharmajri EPIP, Phase I (Extn) Bhatoli Kalan, Baddi - 173 205 India.
Corresponding Author E-mail:dgmtechnical@venusremedies.com
Abstract: A newly developed extended spectrum fourth generation cephalosporins cefepime, has been shown to have good activity against both gram negative organisms. Amikacin is an aminoglycoside antibiotic used to treat different types of bacterial infections. Potentox, a Fixed Dose Combination (FDC)of cefepime and amikacin has a wider range of susceptibility to any of these drugs individually. The in vitro and in vivo effectiveness of Potentox was studied using a high inoculum of an extended spectrum b-lactamase producing Citrobacter braaki, Mycobacterium smegmatis, Acinetobacter baumanii and Neisseria mucosa strain. This study was aimed at evaluating microbial efficacy of Potentox, a FDC of cefepime and amikacin, in comparison with cefepime and amikacin alone. Efficacy was evaluated on the basis of Minimum Inhibitory Concentration (MIC), Antibiotic Susceptibility Test (AST) analysis in C. braaki, M. smegmatis, A. baumanii and Neisseria mucosa. In case of C. braaki, M. smegmatis, A. baumanii and Neisseria mucosa MIC were found to be in potentox 0.421mg/l, 0.625mg/l, 0.342mg/l and 0.423 mg/l. In cefepime alone the MIC were found to be 1.67mg/l, 0.52mg/l, 0.84mg/l and 2.67 mg/l respectively and in amikacin alone the MIC were found to be 3.34mg/l, 1.67mg/l, 2.67mg/l and 1.0mg/l respectively. Antibiotic susceptibility result are given below. In all organisms under study, potentox was found to have more bacterial inhibiting properties than cefepime and amikacin alone in vitro.
Keywords: MIC; Cefepime; Amikacin; Potentox Back to TOC